Both TEGSEDI and WAYLIVRA are legacy assets that were originally brought to the EU market via an Ionis subsidiary, Akcea ...

The new CEO Richard Ascroft brings more than 30 years of industry experience, including senior roles at Takeda ...

Japan’s largest drugmaker Takeda presented final results from a Phase II trial evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody, in patients with persistent or ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS ...

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to ...

Tempus AI TEM, a Chicago-based company focused on precision medicine, is building network effects via its three ...

A combination featuring Exelixis’ experimental drug zanzalintinib has beaten Bayer’s gastrointestinal cancer med Stivarga in ...

Takeda Investor Conference Call and Webcast Details Takeda will host an investor call regarding this update on Sunday, June 1, 6-6:45 pm CDT/ 7-7:45 pm EDT / Monday, June 2, 08:00-08:45 (JST).

A team at Kobe University has created a game-changing resource for autism research: 63 mouse embryonic stem cell lines, each ...

CSL's R&D chief says the company's new hereditary angioedema treatment is one of only a few drugs to be built from scratch in ...